Gaucher disease is the most prevalent lysosomal storage disease and it results from inherited deficient glucocerebrosidase activity. The glucocerebrosidase gene from normal people was sequenced by several laboratories and it was noted that a G or A nucleotide may be present at cDNA position 1601, resulting in 49ar-ginine or 495histidine in the glucocerebrosidase polypeptide. In order to rule out the possibility of cloning error and to elucidate the genetic status of the two genotypes and their distribution in the population, we have developed a convenient and reliable method for the molecular screening of the 1601G and 1601A genotypes in the population. This method uses PCR amplification of glucocerebrosidase genomic DNA in blood samples, followed by BsaHI restriction fragment length polymorphism analysis.
gene from normal people was sequenced by several laboratories and it was noted that a G or A nucleotide may be present at cDNA position 1601, resulting in 49ar-ginine or 495histidine in the glucocerebrosidase polypeptide. In order to rule out the possibility of cloning error and to elucidate the genetic status of the two genotypes and their distribution in the population, we have developed a convenient and reliable method for the molecular screening of the 1601G and 1601A genotypes in the population. This method uses PCR amplification of glucocerebrosidase genomic DNA in blood samples, followed by BsaHI restriction fragment length polymorphism analysis. Out of the 256 subjects without Gaucher disease and 15 Gaucher patients surveyed, the 1601G genotype was present in the homozygous form in all of the asymptomatic subjects and 14 Gaucher patients. In one Gaucher patient who was diagnosed as having type 1 (non-neuropathic) Gaucher disease with the A1226G/T1366G mutations, the heterozygous 1601G/A genotype was detected. These findings indicate that the 1601G genotype which encodes 495arginine ofthe glucocerebrosidase polypeptide is not a cloning error. Instead, it constitutes the normal as well as predominant genotype in the population in the municipality of Greater Victoria, British
Columbia. The 1601A genotype, on the other hand, appears to be quite infrequent in this population. The availability of our restriction enzyme based method has allowed the screening and frequency de status and physiological role of the 1601A and 1601G alleles in Gaucher disease, it is important to develop an accurate and convenient method for molecular screening of the two genotypes in the population. In this paper, we describe a relatively simple method that uses selective PCR amplification of glucocerebrosidase genomic DNA from blood samples and restriction endonuclease analysis for the identification of the 1601A and 1601G genotypes. We also present the findings of our molecular screening of these two genotypes in 256 randomly selected subjects asymptomatic for Gaucher disease in the municipality of Greater Victoria, British Columbia, Canada.
Anonymous human venous blood samples were provided by the Department of Laboratory4Vledicine of the Greater Victoria Hospital Society. These samples had been drawn for routine clinical chemistry or haematology testing and were donated to this research laboratory rather than being discarded. All of the donors were asymptomatic for Gaucher disease. The blood was stored in EDTA vacutainers at 4°C for up to 72 hours.
A three stage method was devised in order to amplify selectively from whole blood the glucocerebrosidase functional gene, and not the pseudogene which shares more than 96% sequence similarity with the functional gene.5
In the first stage, the blood samples were frozen at -20°C overnight and thawed at room temperature for the lysis of the blood cells. Figure 1 Selective PCR amplification of glucocerebrosidase exon 11 for BsaHI restriction endonuclease analysis. In the first amplification, primers A and B were used to amplify glucocerebrosidase exons 9-11 of the functional gene and not the pseudogene. The DNA fragment amplified was then used as template in the second and nested PCR amplification of glucocerebrosidase exon 11, where the G or A nucleotide is located at cDNA position 1601.459 Please refer to the text for details of the PCR amplification and table 1 for the nucleotide sequence of the primers. 20, and 500 mmol/l KCI). To ensure complete lysis of the blood cells and denaturation of the haemoglobin, the sample was subjected to 20 thermal cycles at 90°C and 500C for one minute, respectively. The heat treated blood samples were then used as genomic template.
In the second stage, a nested PCR procedure was used for the selective amplification of glucocerebrosidase functional gene. As shown in fig 1, In view of this finding and the results of our molecular screening, the 1601A genotype is a normal glucocerebrosidase allele that occurs at a low frequency in the municipality of Greater Victoria, British Columbia. As its frequency is less than 1 %, it cannot be defined as a polymorphism in this population. However, the distribution of the two genotypes in other populations may be quite different. The availability of our restriction enzyme based method has allowed accurate molecular screening of these alleles and frequency determination in other populations.
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